Dry Eye Rescue Is Offering Friends Of MDA A 20% Discount On All Products To Help With Your Eye Conditions
Click Here To Save Now
Oct 30, 2025
Author(s): Sydney M Crago Key Takeaways Iron dysregulation contributes to oxidative stress, inflammation, and ferroptosis, driving retinal degeneration in dry AMD and GA. Transferrin, regulating iron homeostasis, is a potential…
Oct 24, 2025
Author(s): Lynda Charters Key Takeaways Gene therapy for nAMD offers potential to reduce treatment burden and improve vision, but long-term safety and efficacy remain concerns. Various gene delivery systems, including…
Oct 16, 2025
By: Roland Mattern Fact checked by: Christine Klimanskis, ELS Key takeaways: Accessibility features in mainstream technology are not as reliable as those in dedicated assistive devices. Purpose-built assistive technology has…
Oct 10, 2025
Sharper vision starts here Author(s)Jack M. Chapman, MD Fact checked by: Sheryl Stevenson Key Takeaways Over 75% of cataract patients have preoperative corneal astigmatism, yet toric IOLs are used in only…
Oct 10, 2025
Permission was given by Martha Steele & Ellen Gould to share this podcast.
Oct 8, 2025
Publication|Articles|October 6, 2025 Optometry Times Journal September/October digital edition 2025- Volume 17 – Issue 05 Author(s)Lynda Charters Fact checked by: Karen S. DeLoss, OD, FAAO Eye care providers are uniquely positioned to…
Sep 26, 2025
Helping with reading, driving, and daily tasks, caregivers often serve as the ‘eyes’ for their loved ones By: Paul Wynn,AARP In her early 40s, Jan* began noticing subtle but troubling…
Sep 23, 2025
A new eyedrop has shown early success in delivering protective compounds to where they’re needed most in the eye, raising hopes for less invasive treatment of serious vision conditions. The…
Sep 23, 2025
Adult Stem Cells Show Therapeutic Promise in Treating Vision Loss From Macular Degeneration by: Michigan Medicine-University of Michigan Newswise — In the United States, age-related macular degeneration is a leading…
Sep 16, 2025
Recruiting- Phase 2 ClinicalTrials.gov IDNCT06635148 SponsorJanssen Research & Development, LLC Information Provided byJanssen Research & Development, LLC Clinical Trial Study Start (Actual)2024-09-19 Primary Completion (Estimated) 2029-08-24 Study Completion (Estimated)2030-06-27 Enrollment (Estimated)311…
Sep 16, 2025
By:Anthony DeFino Fact checked by: Christine Klimanskis, ELS Key takeaways: SAR402663 is a one-time intravitreal gene therapy designed to reduce treatment burden. It is currently being investigated in a phase…
Sep 12, 2025
Author(s): Martin David Harp Key Takeaways TearCare System’s inclusion in TFOS DEWS III report validates its clinical efficacy and role in dry eye management. Data from studies such as SAHARA…
Sep 9, 2025
Author(s): Lynda Charters Key Takeaways Inferred sensitivity mapping predicts retinal function in GA with high spatial resolution, avoiding extensive psychophysical testing. Current GA treatments slow progression but lack functional benefits;…
Sep 2, 2025
By: Jordana Joy, Associate Editor The study will be evaluating the safety, tolerability, and efficacy of QLS-111 in adult patients with normal tension glaucoma. The first patient has been dosed…
Sep 2, 2025
August 28, 2025 By Kyra Dorgeloh, OD, FAAO Thomas A. Wong, OD, FAAO Glaucoma is a general term for a diverse group of complex disorders characterized by progressive degeneration of the…
Aug 26, 2025
By: Alex Young Fact checked by : Christine Klimanskis, ELS Key takeaways: VG801 is a dual-AAV gene therapy in development for the treatment of Stargardt disease. The therapy is under investigation…
Aug 15, 2025
Author(s): Lynda Charters Fact checked by: Karen S. DeLoss, OD, FAAO Key Takeaways Ocular exams can reveal cardiovascular health issues, especially in women, whose symptoms often differ from traditional expectations.…
Aug 12, 2025
Author(s): Lynda Charters Key Takeaways Minimally invasive cosmetic procedures can cause rare but severe ophthalmological complications, including irreversible vision loss from central retinal artery occlusion. Prevention is crucial due to…
Aug 11, 2025
ByJay S. Duker, MD ByAlex Young ByAnthony DeFino Fact checked by Christine Klimanskis, ELS Key takeaways: More than 400 patients have been enrolled in the LUCIA trial investigating Duravyu. EyePoint…
Aug 11, 2025
Published August 6, 2025 | Originally published on ScienceDaily Top Health A new article appearing in the current issue of the peer-reviewed Journal of Agriculture and Food Chemistry explores the concept of “superfoods” and makes…
Aug 6, 2025
Key takeaways: The NEW DAY study did not meet its primary endpoint but showed good outcomes in secondary endpoints. A post hoc analysis achieved its primary endpoint. LONG BEACH, Calif.…
Aug 5, 2025
A new study is being conducted on geographic atrophy. They would like to hear about your experience with the drug Izervay. This is a 60-minute phone interview. Please contact Grace,…
Jul 31, 2025
Author(s): Jordana Joy Key Takeaways LUMIFY Preservative Free eye drops are statistically non-inferior to LUMIFY in reducing ocular redness, with similar efficacy and safety profiles. The study involved 380 participants,…
Jul 28, 2025
July 24, 2025 by Lynda Charters, Jordana Joy, Associate Editor Rain Eye Drops LLC announced the launch of a newly refined first-of-its-kind RainDrop Dispenser Aid created specifically for single-use preservative-free…
Jul 24, 2025
By: The Endocrine Society A novel AI-powered retina tracker can analyze retinal images with near-perfect accuracy in under one second, according to a study being presented Monday at ENDO 2025, the…
Jul 24, 2025
By: Justin Cooper Fact checked by: Christine Klimanskis, ELS Key takeaways: Danegaptide could be an oral therapy for patients with moderate to severe nonproliferative diabetic retinopathy. The treatment was well…
Jul 24, 2025
By: Jordana Joy, Associate Editor Survey participants cited cost concerns, perceived inevitability, and deprioritization as obstacles to receiving eye care.
Jul 24, 2025
By: Anthony DeFino Fact checked by: Christine Klimanskis, ELS Key takeaways: SAR446597 is designed to inhibit C1s and factor Bb in the complement pathway. Fast-track designation expedites the development and…
Jul 8, 2025
Author(s): Martin David Harp Key Takeaways Alcon’s acquisition of LumiThera includes a PBM device for early and intermediate dry AMD, enhancing its non-invasive treatment portfolio. LumiThera’s PBM device demonstrated significant…
Jul 8, 2025
A university study shows certain types of retina problems are early signs of stroke. Research scientists from the University of Sydney in Australia screened the eyes of 3,654 healthy adults…